1-7 of 7
David S. Mendelson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (23): 5918–5926.
https://doi.org/10.1158/1078-0432.CCR-14-1143
Published: 30 November 2014
View article titled, An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
Open the PDF for An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

Johanna C. Bendell, Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Yijun Yang, Ty McClure, Kenneth M. Attie, Matthew L. Sherman, Sunil Sharma
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (2): 480–489.
https://doi.org/10.1158/1078-0432.CCR-13-1840
Published: 16 January 2014
View article titled, Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
Open the PDF for Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer

Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan Goldman, David S. Mendelson, William D. Figg, Shawn Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon, Charles P. Theuer, Bryan R. Leigh, Michael S. Gordon
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4820–4829.
https://doi.org/10.1158/1078-0432.CCR-12-0098
Published: 30 August 2012
View article titled, A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
Open the PDF for A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer in another window
Journal Articles

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

Geoffrey I. Shapiro, Raoul Tibes, Michael S. Gordon, Bryan Y. Wong, Joseph Paul Eder, Mitesh J. Borad, David S. Mendelson, Nicholas J. Vogelzang, Bruno R. Bastos, Glen J. Weiss, Cristian Fernandez, William Sutherland, Hitoshi Sato, William E. Pierceall, David Weaver, Scott Slough, Ernesto Wasserman, Donald W. Kufe, Daniel Von Hoff, Takumi Kawabe, Sunil Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (10): 3431–3442.
https://doi.org/10.1158/1078-0432.CCR-10-2345
Published: 15 May 2011
View article titled, Phase I Studies of CBP501, a G<sub>2</sub> Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I Studies of CBP501, a G<sub>2</sub> Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules

Ranjana H. Advani, Herbert I. Hurwitz, Michael S. Gordon, Scot W. Ebbinghaus, David S. Mendelson, Heather A. Wakelee, Ute Hoch, Jeffrey A. Silverman, Nancy A. Havrilla, Craig J. Berman, Judith A. Fox, Roberta S. Allen, Daniel C. Adelman
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2167–2175.
https://doi.org/10.1158/1078-0432.CCR-09-2236
Published: 31 March 2010
View article titled, Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Open the PDF for Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules in another window
Journal Articles

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan-Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 699–710.
https://doi.org/10.1158/1078-0432.CCR-09-1365
Published: 14 January 2010
View article titled, Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

Linda L. Garland, Manuel Hidalgo, David S. Mendelson, David P. Ryan, Banu K. Arun, Jennifer L. Lovalvo, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Joseph P. Eder
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (14): 4274–4282.
https://doi.org/10.1158/1078-0432.CCR-05-2507
Published: 20 July 2006
View article titled, A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors in another window